
RealRate

PHARMACEUTICAL 2017

MABVAX THERAPEUTICS HOLDINGS INC. Rank 268 of 313



RealRate

PHARMACEUTICAL 2017

MABVAX THERAPEUTICS HOLDINGS INC. Rank 268 of 313

The relative strengths and weaknesses of MABVAX THERAPEUTICS HOLDINGS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MABVAX THERAPEUTICS HOLDINGS INC. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 265% points. The greatest weakness of MABVAX THERAPEUTICS HOLDINGS INC. is the variable Net Income, reducing the Economic Capital Ratio by 313% points.

The company's Economic Capital Ratio, given in the ranking table, is -657%, being 241% points below the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	4,294
Cost of Goods Sold	0
Intangible Assets	6,826
Liabilities, Current	5,691
Liabilities, Non-Current	2,987
Other Assets	169
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-997
Property and Equipment	732
Research and Development	7,801
Revenues	148
Selling, General and Administrative Expense	9,010

Output Variable	Value in 1000 USD
Assets	12,020
Liabilities	8,678
Expenses	16,811
Stockholders Equity	3,343
Net Income	-17,660
Comprehensive Net Income	-17,660
Economic Capital Ratio	-657%